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Most of our knowledge of the effects of aging on the hematopoietic system comes from studies in animal
models. In this study, to explore potential effects of aging on human hematopoietic stem and progenitor cells
(HSPCs), we evaluated CD34þ cells derived from young (<35 years) and old (>60 years) adult bone marrow
with respect to phenotype and in vitro function. We observed an increased frequency of phenotypically
deﬁned stem and progenitor cells with age, but no distinct differences with respect to in vitro functional
capacity. Given that regeneration of peripheral blood counts can serve as a functional readout of HSPCs, we
compared various peripheral blood parameters between younger patients (50 years; n ¼ 64) and older
patients (60 years; n ¼ 55) after autologous stem cell transplantation. Patient age did not affect the number
of apheresis cycles or the amount of CD34þ cells harvested. Parameters for short-term regeneration did not
differ signiﬁcantly between the younger and older patients; however, complete recovery of all 3 blood lin-
eages at 1 year after transplantation was strongly affected by advanced age, occurring in only 29% of the older
patients, compared with 56% of the younger patients (P ¼ .009). Collectively, these data suggest that aging has
only limited effects on CD34þ HSPCs under steady-state conditions, but can be important under consitions of
chemotoxic and replicative stress.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION age seems to have only a limited impact on the phenotype
The bone marrow (BM) is one of the body’s most highly
self-renewing tissues. Hematopoietic stem cells (HSCs) are
capable of replenishing all blood cell types during the com-
plete lifespan of an organism. The hematopoietic systemdoes
not escape the effects of aging, however. In humans, these
effects are manifested clinically by an increased incidence
of myeloproliferative diseases, including leukemia [1-3],
decreased adaptive immunity [4-6], and increased pro-
pensity for anemia [7,8]. Experimental studies in the murine
system comparing young and old HSCs have demonstrated
skewing toward a more myeloid-biased output [9-11], a
relative increase in phenotypically deﬁned HSCs [10-14], and
diminished competitive repopulating ability of old murine
HSCs [10-12].
Until recently, data on age-associated changes in human
hematopoietic stem and progenitor cells (HSPCs) were
limited. Two recent studies that addressed this issue sug-
gested that, although some of the ﬁndings observed in the
murine system could be conﬁrmed in humans, increasingdgments on page 870.
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14.03.001and functional in vitro and in vivo properties (as examined in
xenotransplant models) of human HSPCs [15,16].
In this study, we investigated CD34þ cells derived from
normal BM (NBM) of healthy young and elderly individuals
with respect to phenotype and in vitro function. To study the
impact of aging and stress response on human HSPCs in vivo,
we analyzed the impact of age on HSPC mobilization and
short-term and long-term regeneration after autologous
stem cell transplantation (ASCT). A better understanding of
HSPC aging will facilitate the development of more suitable
treatment regimens for elderly patients undergoing ASCT.MATERIALS AND METHODS
NBM
After achieving informed consent, BM aspirates were obtained from
patients age >60 years who underwent total hip replacement, volunteers
age 18 to 35 years, and young healthy potential donors for hematopoietic
ASCT who underwent BM aspiration as part of a standard medical exami-
nation. NBM from 9 young healthy volunteers and 2 young potential donors
was used for in vitro experiments. Young NBM samples for the microarray
analysis came from 9 young healthy volunteers and 1 young potential donor.
All older NBM samples came from patients undergoing total hip replace-
ment. The protocol for NBM collection was approved by the Institutional
Review Board of the University Medical Center Groningen. All participants
had normal general health and normal peripheral blood counts and an
absence of hematologic disorders. Details of the experiments performed on
the NBM samples are presented in Supplemental Table 1.Flow Cytometry Analysis and Sorting Procedures
The ﬂow cytometry and sorting procedures are described in detail in the
Supplemental Materials.Transplantation.
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A colony-forming cell (CFC) assay was performed in methylcellulose
(MethoCult H4230; StemCell Technologies, Grenoble, France), supplemented
with 20 ng/mL IL-3, 20 ng/mL IL-6, 20 ng/mL granulocyte colony-stimulating
factor (G-CSF), 20 ng/mL c-Kit ligand, and 1 U/mL erythropoetin (Cilag Eprex,
Brussels, Belgium), as described previously [17]. The assay was performed in
duplicate. At 2 weeks after plating, colony-forming unitegranulocyte/
macrophage (CFU-GM), burst-forming uniteerythroid (BFU-E), and colony-
forming unitegranulocyte erythrocyte monocyte megakaryocyte (CFU-
GEMM) numbers were measured and recorded.
For the long-term cultures, CD34þ cells were plated in bulk in 12-well
plates or, for limiting dilution experiments, in a 96-well plate precoated
with MS5 stromal cells. Cells were expanded in long-term culture (LTC)
medium (a-minimum essential medium supplemented with heat-
inactivated 12.5% FCS; Sigma-Aldrich, Zwijndrecht, The Netherlands),
heat-inactivated 12.5% horse serum (Sigma-Aldrich), penicillin and strep-
tomycin, 2 mM glutamine, 57.2 mM b-mercaptoethanol (Sigma-Aldrich), and
1 mM hydrocortisone (Sigma-Aldrich), supplemented with 20 ng/mL IL-3,
20 ng/mL G-CSF (Rhone-Poulenc Rorer, Amstelveen, The Netherlands), and
20 ng/mL thrombopoietin (Kirin, Tokyo, Japan). Cultures were maintained at
37 C in 5% CO2 and were demi-depopulated weekly for medium changes. In
the MS5 cocultures, cells were counted weekly.
For the long-term culture initiating cell (LTC-IC) limiting dilution assay,
5 weeks of expansion was followed by the removal of suspension cells and
addition of methylcellulose (StemCell Technologies) as described for the CFC
assay. Two weeks later, wells containing CFCs were scored as positive, and
the LTC-IC frequency was calculated using L-Calc software for limiting
dilution analysis (StemCell Technologies). Liquid cultures were performed
exactly as described for the cocultures, but without coculturing of MS5.Transplantation Procedure
Details on the apheresis and transplantation procedures are provided in
the Supplemental Material.Clinical Cohort of ASCT Recipients
A cohort of 119 ASCT recipients was retrospectively studied. All subse-
quent patients with multiple myeloma (MM) or non-Hodgkin lymphoma
(NHL) age 50 years or 60 years treated with high-dose chemotherapy
followed by ASCT at the Department of Hematology, University Medical
Center Groningen between June 1993 and June 2007 were included in this
study. Patients who experienced progressive or relapsing disease within
1 year after ASCT were excluded from the analysis. Within the NHL group,
only patients with diffuse large B cell lymphoma or mantle cell lymphoma
were included. The younger age group (50 years) comprised 64 patients
(mean age, 44  7 years), including 27 with NHL and 37 with MM. The older
age group (60 years) included 55 patients (mean age, 63 2 years), with 18
with NHL and 37 with MM. All patients with MM underwent ASCT upfront
after induction therapy with vincristine, adriamycin, and dexamethasone
(VAD) or with thalidomide, adriamycin, and dexamethasone (TAD) [18-20].
All patients with NHL underwent ASCT as second-line treatment, after ﬁrst-
line treatment with 6 to 8 cycles of (Rituximab), Cyclophosphamide,
Hydroxydaunorubicin, Vincristine (Oncovin), Prednisone [(R)-CHOP]
chemotherapy. Reinduction treatment consisted of (R) Cisplatin, Cytarabine,
Dexamethasone [(R)-DHAP] followed by (R) Etoposide, Ifosfamide, Metho-
trexaat (R)-VIM and a second course (R)-DHAP chemotherapy [21]. Patients
with MM were conditioned with high-dose melphalan (200 mg/m2)
(n ¼ 70), cyclophosphamide þ total body irradiation (n ¼ 2), or Carmustine,
Etoposide, Cytarabine, Melphalan (BEAM) (n ¼ 2). Patients with NHL were
conditioned with BEAM (n ¼ 45).
After infusion of peripheral blood stem cells (PBSCs), the number of days
needed to reach a granulocyte count of at least 0.5  109/L and to reach a
thrombocyte count of at least 20  109/L was recorded for each patient.
Moreover, cell counts were measured on day 28, day 40, and 1 year after
ASCT. A leukocyte count of  4  109/L, thrombocyte count of 150  109/L,
and hemoglobin (Hb) level of 7.5 mmol/L for women and 8.7 mmol/L for
men were considered normal values in this analysis.Statistical Analysis
The Mann-Whitney U test or c2 test was used for analysis of individual
group differences. Hematologic recovery was assessed using Kaplan-Meier
probability curves, and statistical comparison of curves was performed us-
ing the log-rank test. The prognostic value of different variables for proba-
bility of hematologic recovery was assessed by univariate and multivariate
analyses using a Cox multiple regression model. Differences with a P value
.05 were considered statistically signiﬁcant.RESULTS
Age-Associated Phenotypic Changes Within the Human
Hematopoietic System
To investigate whether the aging process has an effect on
the composition of the different stem and progenitor cells
populations within the total cell population, we performed
phenotypic analyses of the total mononuclear cell fraction in
young (age<35 years) andold (age>60 years) adultNBM. The
percentages of total CD34þ cells, progenitor cellecontaining
CD34þCD38þ cells, and multipotent CD34þCD38 fractions
increased signiﬁcantly from young NBM (n ¼ 5) to old NBM
(n ¼ 8) (Figure 1A). Subsequent analysis of the frequency of
common myeloid progenitors, granulocyte macrophage pro-
genitors, and megakaryocyte erythrocyte progenitors within
the CD34þCD38þ fraction revealed no signiﬁcant differences
between young NBM (n¼ 4) and old NBM (n¼ 4) (Figure 1B).
In contrast, the percentage of lymphoid progenitors, deﬁned
as CD34þCD10þ cells within the total CD34þ cell population,
was signiﬁcantly lower in old NBM (P ¼ .021) (Figure 1C).
Impact of Aging on HSPC Function In Vitro
We performed several in vitro assays to study the func-
tional capacity of CD34þ cells derived from young and old
adult NBM. The colony-forming potential of CD34þ cells for
all included lineages was comparable in young NBM (n ¼ 6)
and old NBM (n ¼ 5) (Figure 1D). In addition, the LTC-IC
frequency, an established in vitro measurement for HSPCs,
was comparable in young and old adult NBM-derived CD34þ
cells (Figure 1E).
To further assess the impact of age on function and dif-
ferentiation potential of CD34þ human cells, we cultured the
cells in liquid and MS5 cocultures. As in the other in vitro
assays, we found no signiﬁcant difference in growth between
CD34þ cells derived fromyoung adult NBM (n¼ 4) and those
derived from old adult NBM (n ¼ 4) (Figure 1F). In addition,
we observed no differences in serial replating capacity
assessed in the MS5 cocultures between young NBM and old
NBM (data not shown). Taken together, these ﬁndings indi-
cate very similar in vitro functional capacities of young and
old adult NBM, as measured in the different in vitro assays.
Our observation that young and old NBM CD34þ cells are
quite comparable in steady-state conditions was conﬁrmed
by the results of our microarray-based gene expression an-
alyses of CD34þ cells derived from young NBM (n ¼ 10) and
old NBM (n ¼ 22). We found a very limited number of
differentially expressed genes, with 18 up-regulated probes
representing 14 annotated genes (P < .00001, Student t test)
(Supplemental Table 2).
HSPCs In Vivo
To follow up on our in vitro research on the impact of
aging on human HSPC function, we extended our research to
an in vivo situation, studying ASCT. In this setting, we studied
mobilization and apheresis of PBSCs and compared regen-
eration data in a group of 64 younger patients (age
50 years) and a group of 55 older patients (age 60 years)
after ASCT. Patients with progressive or relapsing disease
within 1 year after ASCT were excluded from our analysis.
Patient characteristics are summarized in Table 1.
Mobilization and Apheresis
Different mobilizing therapy regimens were used, with
the percentages of patients receiving any 1 of these therapies
not differing signiﬁcantly in the 2 age groups (Table 1). The
target for cell harvest was 5106 CD34þ cells/kg for patients
Figure 1. Phenotypic changes and in vitro function of HSPCs with aging. (A) Percentages of total CD34þ cells, progenitor-containing CD34þCD38þ cells, and mul-
tipotent CD34þCD38 cells in the mononuclear cell fraction of young NBM (n ¼ 5) and old NBM (n ¼ 8). (B) Percentages of cells phenotypically deﬁned as common
myeloid progenitor (CMP), granulocyte macrophage progenitor (GMP), or megakaryocyte erythroid progenitor (MEP) cells within the CD34þCD38þCD10 cell
population. On the right are representative FACS plots with the gating strategy for each sample group. Data are mean  SD. *P < .05. (C) Percentages of cells with a
lymphoid progenitor phenotype, deﬁned as CD10þ cells within the CD34þ cell population. *P < .05. (D) Results of in vitro CFC assay for young NBM (n ¼ 6) and old
NBM (n ¼ 5). Bars represent mean number of colonies  SD. (E) Testing of in vitro HSPC frequency with a long-term culture-initiating cell assay, with results
indicating the frequency in proportion as calculated by L-CALC, in which, for example, a proportion of 0.025 indicates a stem cell frequency of 1 in 40. Horizontal lines
indicate mean frequency per group. Frequencies are the mean frequencies per group of young BM (n ¼ 6) and old BM (n ¼ 5). (F) Results of liquid culture and (G) MS5
cocultures for young NBM (n ¼ 4) and old NBM (n ¼ 4). Data are mean  SD.
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The number of apheresis days necessary to achieve these
targets was not signiﬁcantly different in the 2 age groups
(Table 2), In addition, there was no signiﬁcant difference in
the median number of CD34þ cells collected on the ﬁrst day
of apheresis in the 2 age groups. On the ﬁrst day of apheresis,
11  106 CD34þ cells/kg were collected from the younger
patients with MM, and 13  106 CD34þ cells/kg were
collected from the older patients with MM. For patients with
NHL, cell collection on the ﬁrst day of apheresis was
11.6  106 CD34þ cells/kg in the younger patients and
9.6  106 CD34þ cells/kg in the older patients (Table 2).
No Age-Related Effect on the Colony-Forming Potential of
PBSC Material
Routine CFU-GM assays were performed on a small
aliquot of the collected autologous transplant material. CFU-
GM data were available for all 119 patients in our cohort.
The mean CFU-GM value was 34  29  104/kg (median,
28  104/kg) in the younger patients and 33  23  104/kg(median, 29  104/kg) in the older patients. CFU-GM
numbers did not differ signiﬁcantly between patients with
MM and those with NHL in the age <50 years or age >60
groups. In addition, there was no inverse correlation be-
tween age and CFU-GM colony formation (data not shown).
Regeneration of Peripheral Blood Cell Counts after ASCT
To gain insight into the in vivo function of the CD34þ cells
used for ASCT, we compared various peripheral blood cell
parameters in the younger and older patients. The parame-
ters studied are considered representative of short-term
hematologic recovery after ASCT. The mean number of days
after stem cell infusion needed to achieve a granulocyte
count of at least 0.5  109/L was 18.5  11.1 days in the
younger patients and 22.8  20.9 days in the older patients
(Table 2), a nonsigniﬁcant difference. A signiﬁcant difference
was seen in the percentage of patients with a granulocyte
count of 0.5  109/L at day 28 post-ASCT (18% of the older
patients versus 4.9% of the younger patients; P ¼ .03). For
platelets, as for granulocytes, the mean number of days after
Table 1
Patient Characteristics
Characteristic Age 50 yr Age 60 yr P Value
Total, n 64 55
NHL, n 27 18
MM, n 37 37
Age, yr, mean  SD 44  7 63  2 <.0001
Male sex, % 65 57 .50
NHL
Chemotherapy courses before
mobilization, mean  SD
7.2  3.1 6.6  2.9 .50
(R)-CHOP, % 100 100 1.0
Mobilizing chemotherapy, %
(R)-DHAP 77 50 .20
High-dose ara-C 12 38 .06
CHOP 12 0 .50
Cyclophosphamide 0 6 .50
G-CSF alone 0 6 .50
Conditioning chemotherapy, %
BEAM 100 100
MM
Chemotherapy courses before
mobilization, mean  SD
3.3  0.8 4  3.4 .20
VAD, % 56 67 .50
PAD, % 25 16 .60
TAD, % 19 17 1.0
Mobilizing chemotherapy, %
CAD 62 75 .30
Cyclophosphamide 38 25
Conditioning chemotherapy, %
High-dose melphalan 95 94 1.0
Cyclophosphamide/total body
irradiation
6
BEAM 5
PAD, Bortezomib, Doxorubicin, Dexamethasone; CAD, Cyclophosphamide,
Doxorubicin, Dexamethasone.
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20  109/L without platelet transfusion was not signiﬁ-
cantly different between the younger and older patients
(Table 2).
Although the younger and older patients received compa-
rable CD34þ cell doses for ASCT, at 1 year after transplantation,
a signiﬁcant percentage of the older patients did not experi-
ence complete recovery of peripheral blood counts. Slightly
more than half (56%) of the younger patients had normal pe-
ripheral blood counts at 1 yearafter transplantation, compared
with only 29% of the older patients (P ¼ .009) (Figure 2). Pe-
ripheral blood cell counts of the younger and older patients atTable 2
Results of Apheresis and Regeneration of Peripheral Blood Counts after ASCT
Variable
Apheresis
CD34þ cells collected at day 1,  106/kg, median
MM
NHL
Patients achieving target CD34þ cell number by mobilization, %
At day 1
At day 2
At day 3
At day 4
Transplantation
Number of infused CD34þ cells,  106/kg, mean  SD (median)
Regeneration
Days to granulocytes 0.5  109/L, mean  SD (median)
Patients with granulocytes 0.5  109/L at day 28, %
Days to thrombocytes >20  109/L, mean  SD (median)
Patients with thrombocytes >20  109/L at day 40, %
Patients with normal peripheral blood counts of Hb, leukocytes,
and thrombocytes after 1 yr, %1 year post-ASCT are provided in Supplemental Table 3. Older
patients had a signiﬁcantly lowermeanHb level at 1 year post-
ASCTcomparedwith younger patients (mean, 8.0 0.7mmol/
L versus 8.5 0.8mmol/L; P¼ .0009), aswell as a considerably
lowermeanplatelet count (147 61 versus 169 57; P¼ .06).
Leukocyte counts at1yearpost-ASCTwere comparable in the2
groups.
The effect of age on complete recovery of peripheral blood
counts at 1 year after transplantation was most pronounced
in the patients with NHL. In this group, 40% of the younger
patients experienced complete recovery of peripheral blood
counts by 1 year post-ASCT, compared with none of the older
patients (Figure 2). Importantly, incomplete recovery was
associated with statistically signiﬁcantly lower platelet,
leukocyte, and Hb levels (Supplemental Table 4).
Independent Effect of Age on Regeneration after ASCT
Other variables besides age found to be correlated with
complete recovery of peripheral blood counts at 1 year post-
ASCT on univariate analysis included number of infused
CD34þ cells, diagnosis (either MM or NHL), short-term re-
generationwith granulocytes (days until a granulocyte count
of 0.5  109/L) and short-term regeneration with platelets
(days until a platelet count of 20  109/L). However, when
these variables were evaluated in a multivariate analysis,
only age at ASCT (P ¼ .02; hazard ratio [HR], 2.4; 95% conﬁ-
dence interval [CI], 1.3 to 4.1) and diagnosis (P ¼ .02; HR, 2.6;
95% CI, 1.2 to 4.0) were identiﬁed as independent prognostic
variables for complete recovery of peripheral blood counts at
1 year post-ASCT.
DISCUSSION
Data on the impact of increasing age on the HSPC
compartment in humans are limited. In agreement with
previously reported data [9-11,15,16,22,23], we found a sig-
niﬁcant decrease in phenotypically deﬁned lymphoid pro-
genitors in older patients and a relative increasewith aging in
the percentages of both CD34þCD38 and CD34þCD38þ cells
in old NBM compared with young NBM. These data do not
provide information on the absolute number of HSPCs in
younger and older human NBM, however, especially given
that BMcellularity decreaseswith age [24,25]. The function of
CD34þ cells derived from NBM of younger versus older in-
dividuals did not differ in various in vitro assays. ApparentlyAge 50 yr Age 60 yr P Value
11 13 .30
11.6 9.6 .70
59 64 .60
30 23 .50
8 7 .90
3 4 .90
8.9  9.7 (5.7) 6.2  4.8 (5.0) .10
18.5  11.1 (16) 22.8  20.9 (16) .20
4.9 18 .03
28.2  46.8 (17) 29.4  25.5 (19) .90
11.5 20.4 .30
56 29.6 .009
Figure 2. Regeneration of peripheral blood cell counts at 1 year post-ASCT.
Graphs present the percentages of patients with normal platelet and leuko-
cyte counts and normal Hb levels in peripheral blood at 1 year post-ASCT
according to age group in all 119 patients (A), in patients with MM (B;
n ¼ 74), and in patients with NHL (C; n ¼ 45). P values are for the differences in
age groups at the 1-year follow-up.
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are quite comparable under steady-state conditions.
It also can be argued that the in vitro assays used in the
present study are not sufﬁciently sensitive to detect potential
age-related effects; however, only limited variation was seen
between samples in1group in the invitro readouts.Moreover,
recent in vivo transplantation studies in NOD/SCID/Il-2Rg null
(NSG) mice with young and old human NBM yielded incon-
sistent results. One study did not reveal differences in the
frequency of NSG-repopulating cells with increasing age [15],whereas another study reported a signiﬁcant difference
(after transplantation of 500 HSCs) in the frequency of
NSG-repopulating cells with age, from approximately 2% to
approximately 1% [16].
Various hypotheses can be proposed to explain the dif-
ference between murine and human studies with respect
to the effect of age on HSCs. One possibility is related to
limitations with the stringent puriﬁcation of human HSCs
compared with murine HSCs, which potentially could mask
potential differences by contaminating progeny. Another
hypothesis is that CD34þ BM-derived cells from older and
younger individuals are comparable under steady-state
conditions, and that potential differences will become
apparent only in stressful conditions, for example, in serial
transplantations with limited cell numbers or chemotherapy.
From this perspective, we used ASCT to study the impact of
age on human HSC function in vivo without xenogeneic
immunologic or metabolic effects and in a clinically relevant
setting.
At present, hematopoietic stem cell transplantation is the
sole well-established clinically applied stem cellebased
therapy. Elderly patients have the greatest need for this form
of treatment. The clinical relevance is also illustrated by a
previous study in a cohort of 98 patients with hematologic
malignancies treated with high-dose chemotherapy fol-
lowed by ASCT, which found that only 39% of patients had
complete recovery of all 3 lineages after 1 year [26]. The
disadvantage of our approach is that regeneration is depen-
dent not only on the age of the transplanted HSPCs, but also
on the effects of intensive chemotherapy on both the HSPCs
and the BM microenvironment. Indeed, the ASCT procedure
has signiﬁcant effects on HSPC function, as we reported
previously in a study of BM of patients at 1 year post-ASCT
[27,28]. Furthermore, as might be true for transplantation
studies in NSG mice, age-related differences in homing
capacity and microenvironmental changes could affect
regeneration.
On the other hand, repetitive cycles of chemotherapymay
serve as a model for the induction of accelerated aging, and
the observed age-related effects might be enhanced and thus
better appreciated. Indeed, we found a signiﬁcant effect on
long-term regeneration, but not on short-term regeneration,
after ASCT, suggesting that older HSCs are more hampered
than younger HSCs by the procedure of chemotherapy,
mobilization, apheresis, transplantation, and regeneration.
This effect seems more pronounced with more intensive
chemotherapy. Patients with NHL received signiﬁcantly
more chemotherapy courses before mobilization of stem
cells compared with patients with MM (younger patients,
P < .0001; older patients, P ¼ .007) and showed a more sig-
niﬁcant effect of age on long-term regeneration.
Although peripheral blood cell counts at 1 year post-ASCT
did not differ signiﬁcantly between the younger and older
patients at the group level, the negative effect of advanced
age on hematopoietic regeneration is clearly shown by the
much higher percentage of patients with incomplete recov-
ery in the older age group compared with the younger age
group. Importantly, incomplete recoverywas associatedwith
statistically signiﬁcantly lower platelet, leukocyte, and Hb
levels. This might lead to signiﬁcant clinical problems; for
example, incomplete recovery might limit treatment options
for relapsing disease after ASCT owing to decreased hema-
tologic tolerance to chemotherapy and radiation. Moreover,
as a result of impaired regeneration after ASCT, infections in
older patients might induce hematopoietic stress and (pan)
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study cohort, and a (prospective) study including more pa-
tients is needed to conﬁrm our data and further elucidate the
clinical relevance. Nevertheless, our ﬁndings underscore the
need for further research on underlying mechanisms and
ways to improve the ASCT procedure, especially in older
patients.
The upper age limit for ASCT is constantly increasing
[31,32]. One factor directly affecting the feasibility of ASCT is
the mobilization capacity of CD34þ cells. The available data
on the effects of increasing age onCD34þ cellmobilization are
somewhat inconsistent. Several studies have reported poorer
mobilization in elderly patients, but although fewer CD34þ
cellswere collected in these patients, this quantities did reach
the standard target level for performing ASCT inmost studies
[33-35]. Thus, advanced age is not an obstacle for the col-
lection of a stem cell product capable of restoring hemato-
poietic function. In our cohort, we found no quantitative
differences in the numbers of mobilized and collected CD34þ
cells after apheresis. This discrepancy with previous studies
might be related to our relatively small patient cohort, the
attempted mobilization after a course of chemotherapy, or
the volume of peripheral blood used for apheresis. Interest-
ingly, murine studies have shown approximately 5-fold
greater mobilization efﬁciency of primitive hematopoietic
cells fromagedmice, presumably related to reduced adhesion
of hematopoietic progenitor cells to BM stroma [36].
The effects of age on homing of human primitive hemato-
poietic cells remain poorly understood. In murine models, a
reduced seeding efﬁciency of old murine HSPCs compared
with young HSPCs has been observed [14,37]. Moreover, a
time-lapse 2-photon microscopy study revealed that aged
early hematopoietic progenitor cells localize more distantly
from the endosteum, suggesting altered niche biology in the
aged hematopoietic system [38].
Along with the aformentioned extrinsic mechanisms, the
signiﬁcantly lower percentage of older patients with normal
trilineage hematopoiesis after ASCT might be related to
intrinsic stem cell changes [39]. A potential cell intrinsic
contributing factor is telemore shortening, a mechanism
implicated in aging and observed in a setting of chemo-
therapy treatment and ASCT [40,41]. However, assessment of
telomere length after ASCT has revealed inconsistent results
regarding the persistence of shortening in patients [42-45].
Most likely, a combination of both intrinsic and extrinsic
factors is contributing to the age-related observations in
ASCT. Further studies are needed to further elucidate the
underlying mechanisms.
Collectively, the reported data suggest that aging has only
limited effects on CD34þ human HSPCs under steady-state
conditions, as assessed by various in vitro assays. However,
in ASCT recipients, advanced age strongly impairs long-term
regeneration of peripheral blood cell counts. This may sug-
gest that age-related changes in the hematopoietic system
are most important in situations of chemotoxic and replica-
tive stress.
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